Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

WP1122

Other · developed by Moleculin Biotech

Phase 1 Most advanced trial (none active)
MBRX Developer
1 Registered trials

What is WP1122?

WP1122 is an investigational drug studied in Healthy Volunteer.

At a glance

Drug type
Other
Developer
Moleculin Biotech, Inc. (MBRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
54EAA28C5Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05195723 Phase 1 Healthy Volunteer Completed MBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy Volunteer

More from Moleculin Biotech

Liposomal Annamycin Phase 1/2 MOL4239 Phase 2

Follow MBRX, the company behind WP1122

See MBRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MBRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.